{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:10:44Z","timestamp":1783296644442,"version":"3.54.6"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Excellent Youth Foundation of Sichuan Scientific Committee Grant in China","award":["2019JDJQ0008"],"award-info":[{"award-number":["2019JDJQ0008"]}]},{"name":"National Major Scientific and Technological Special Project for \u201cSignificant New Drugs Development\u201d of China","award":["2018ZX09733001"],"award-info":[{"award-number":["2018ZX09733001"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFA0201402"],"award-info":[{"award-number":["2016YFA0201402"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Natural Science Foundation Regional Innovation and Development","award":["U19A2003"],"award-info":[{"award-number":["U19A2003"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.canlet.2020.07.032","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T21:38:21Z","timestamp":1597354701000},"page":"146-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"491","author":[{"given":"Xue","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuquan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2020.07.032_bib1","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2020.07.032_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2559.2010.03696.x","article-title":"Epidemiology of lymphomas","volume":"58","author":"Roman","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2020.07.032_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2020.07.032_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2020.07.032_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2020.07.032_bib6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev-immunol-020711-075027","article-title":"Pathogenesis of human B cell lymphomas","volume":"30","author":"Shaffer","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2020.07.032_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.canlet.2020.07.032_bib8","first-page":"204","article-title":"Diffuse large B-cell lymphoma: current strategies and future directions","volume":"19","author":"Jennifer","year":"2012","journal-title":"Canc. Contr."},{"key":"10.1016\/j.canlet.2020.07.032_bib9","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.4049\/jimmunol.170.6.3263","article-title":"Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3","volume":"170","author":"Niemand","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2020.07.032_bib10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","article-title":"The STATs of cancer--new molecular targets come of age","volume":"4","author":"Yu","year":"2004","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.07.032_bib11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1634\/theoncologist.2013-0407","article-title":"STAT3 inhibitors: finding a home in lymphoma and leukemia","volume":"19","author":"Munoz","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2020.07.032_bib12","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.07.032_bib13","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","article-title":"STATs in oncogenesis","volume":"19","author":"Bowman","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.07.032_bib14","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","article-title":"Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas","volume":"111","author":"Ding","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2020.07.032_bib15","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1200\/JCO.2013.52.8414","article-title":"Transcription factor STAT3 as a prognostic marker and therapeutic target in cancer","volume":"31","author":"Frank","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2020.07.032_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4161\/jkst.22312","article-title":"Nucleic acid-based approaches to STAT inhibition","volume":"1","author":"Sen","year":"2012","journal-title":"JAK-STAT"},{"key":"10.1016\/j.canlet.2020.07.032_bib17","first-page":"136","article-title":"Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors","volume":"1845","author":"Siveen","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2020.07.032_bib18","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1073\/pnas.1424171112","article-title":"Suppression of cancer relapse and metastasis by inhibiting cancer stemness","volume":"112","author":"Li","year":"2015","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2020.07.032_bib19","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/cam4.675","article-title":"Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin","volume":"5","author":"Zhang","year":"2016","journal-title":"Canc. Med."},{"key":"10.1016\/j.canlet.2020.07.032_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2018.04.008","article-title":"BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC","volume":"428","author":"MacDonagh","year":"2018","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.07.032_bib21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s13046-018-0914-0","article-title":"Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells","volume":"37","author":"Zuo","year":"2018","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.07.032_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1756-8722-4-31","article-title":"High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma","volume":"4","author":"ZL","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2020.07.032_bib23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.07.032_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.canlet.2017.09.045","article-title":"Inhibition of pyruvate carboxylase by 1\u03b1,25-dihydroxyvitamin D promotes oxidative stress in early breast cancer progression","volume":"411","author":"Wilmanski","year":"2017","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.07.032_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00666038","article-title":"Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors","volume":"36","author":"Weidner","year":"1995","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.canlet.2020.07.032_bib26","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1007\/s00018-008-8637-6","article-title":"Mcl-1 is a potential therapeutic target in multiple types of cancer","volume":"66","author":"Akgul","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2020.07.032_bib27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/cdd.2009.176","article-title":"Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents","volume":"17","author":"S\u00e1nchez-P\u00e9rez","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2020.07.032_bib28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s10495-013-0829-3","article-title":"MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1","volume":"18","author":"Azijli","year":"2013","journal-title":"Apoptosis"},{"key":"10.1016\/j.canlet.2020.07.032_bib29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/cells3020418","article-title":"Mcl-1 ubiquitination: unique regulation of an essential survival protein","volume":"3","author":"Mojsa","year":"2014","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2020.07.032_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.canlet.2020.07.032_bib31","first-page":"989","article-title":"Precision medicine in diffuse large B-cell lymphoma: hitting the target","volume":"100","author":"Vermaat","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2020.07.032_bib32","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1158\/0008-5472.CAN-18-2636","article-title":"Spleen tyrosine kinase\u2013mediated autophagy is required for epithelial\u2013mesenchymal plasticity and metastasis in breast cancer","volume":"79","author":"Shinde","year":"2019","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.07.032_bib33","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/13543784.2017.1351941","article-title":"Do STAT3 inhibitors have potential in the future for cancer therapy?","volume":"26","author":"Wong","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.canlet.2020.07.032_bib34","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1182\/blood-2012-05-428466","article-title":"1Division, Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab\/R-CHOP","volume":"120","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2020.07.032_bib35","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1200\/JCO.2012.45.6004","article-title":"Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP","volume":"31","author":"Huang","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2020.07.032_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","article-title":"Cell death: critical control points","volume":"116","author":"Danial","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2020.07.032_bib37","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1073\/pnas.90.8.3516","article-title":"MCLI, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2","volume":"90","author":"Kozopas","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2020.07.032_bib38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11373-005-9064-4","article-title":"Mcl-1: a highly regulated cell death and survival controller","volume":"13","author":"Yang-Yen","year":"2006","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.canlet.2020.07.032_bib39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","article-title":"Stat3 as an oncogene","volume":"98","author":"Bromberg","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2020.07.032_bib40","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1541-7786.MCR-18-0151","article-title":"Autocrine fibronectin inhibits breast cancer metastasis","volume":"16","author":"Shinde","year":"2018","journal-title":"Mol. Canc. Res."},{"key":"10.1016\/j.canlet.2020.07.032_bib41","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/0008-5472.CAN-10-2380","article-title":"STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma","volume":"71","author":"Scuto","year":"2011","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.07.032_bib42","first-page":"1","article-title":"Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo","volume":"13","author":"Sethi","year":"2014","journal-title":"Mol. Canc."},{"key":"10.1016\/j.canlet.2020.07.032_bib43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2559.2008.03076.x","article-title":"MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type","volume":"53","author":"Yoon","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2020.07.032_bib44","doi-asserted-by":"crossref","first-page":"a014241","DOI":"10.1101\/cshperspect.a014241","article-title":"MYC activation is a hallmark of cancer initiation and maintenance","volume":"4","author":"Gabay","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.canlet.2020.07.032_bib45","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/leu.2012.367","article-title":"MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma","volume":"27","author":"Wenzel","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2020.07.032_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2020.07.032_bib47","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-08-0746","article-title":"Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics","volume":"14","author":"Mita","year":"2008","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.07.032_bib48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0609.2010.01567.x","article-title":"Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL)","volume":"86","author":"Markovic","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.canlet.2020.07.032_bib49","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.febslet.2010.05.061","article-title":"Mcl-1; the molecular regulation of protein function","volume":"584","author":"Thomas","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2020.07.032_bib50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.onc.1204062","article-title":"Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53","volume":"20","author":"Bacus","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.07.032_bib51","first-page":"1604","article-title":"Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase 1","volume":"61","author":"She","year":"2001","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.07.032_bib52","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/carcin\/bgh052","article-title":"The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells","volume":"25","author":"Nguyen","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2020.07.032_bib53","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3390\/molecules22071157","article-title":"2,5-Dihydroxyacetophenone induces apoptosis of multiple myeloma cells by regulating the MAPK activation pathway","volume":"22","author":"Ko","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2020.07.032_bib54","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/1078-0432.CCR-19-0302","article-title":"Bioactivation of napabucasin triggers reactive oxygen species\u2013mediated cancer cell death","volume":"25","author":"Froeling","year":"2019","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.07.032_bib55","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.molmed.2017.03.004","article-title":"ROS in cancer: the burning question","volume":"23","author":"Chio","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.canlet.2020.07.032_bib56","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.gene.2016.04.054","article-title":"MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC","volume":"587","author":"Ma","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.canlet.2020.07.032_bib57","first-page":"339","article-title":"Stat3\/Oct-4\/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066","volume":"53","author":"Cheng","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2020.07.032_bib58","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.onc.1205260","article-title":"Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.07.032_bib59","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.18632\/oncotarget.27274","article-title":"Dynamic transition of the blood-brain barrier in the development of non-small cell lung cancer brain metastases","volume":"10","author":"Uzunalli","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2020.07.032_bib60","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/annonc\/mdn666","article-title":"Angiogenesis and antiangiogenic therapy in non-Hodgkin\u2019s lymphoma","volume":"20","author":"Ruan","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2020.07.032_bib61","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2010.037408","article-title":"High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy","volume":"96","author":"Cardesa-Salzmann","year":"2011","journal-title":"Haematologica"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520303852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520303852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:51:39Z","timestamp":1759593099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383520303852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":61,"alternative-id":["S0304383520303852"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2020.07.032","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2020.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}